ArticleNeuro-oncology advances
Tumor treating fields plus temozolomide maintenance after radiochemotherapy in Chinese grade 4 gliomas: Efficacy and predictive biomarkers.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The EF-14 trial established the survival benefit of adding Tumor Treating Fields (TTFields) to maintenance temozolomide (TMZ) following standard radiochemotherapy in glioblastoma (GBM). Whether this benefit is reproducible in Chinese grade 4 glioma patients in real-world practice-and what biomarkers predict response-remains unknown. This study evaluates TTFields efficacy in a Chinese cohort and explores predictive biomarkers. Methods: We conducted a retrospective analysis of Chinese patients with grade 4 gliomas who underwent surgery and postoperative radiochemotherapy, followed by maintenance TMZ with or without TTFields treatment at Tongji Hospital, Huazhong University of Science and Technology, between November 2019 and November 2024. The Kaplan-Meier method was used to plot survival curves for overall survival (OS) and progression-free survival (PFS), and the log-rank test was applied for group comparisons. Univariate Cox proportional hazards regression analysis was performed to identify factors associated with PFS and OS. Subgroup analyses were conducted, and results were visualized using forest plots. Results: A comprehensive dataset of 64 postoperative grade 4 glioma patient records was compiled in the study. Among them, 22 patients (34.4%) were administered TTFields treatment. The TTFields-treated group demonstrated a significant improvement in OS compared to the non-TTFields-treated group (median OS: 15 months vs. 11 months, Conclusion: In this retrospective cohort of Chinese patients with grade 4 glioma, adding TTFields to maintenance TMZ therapy following standard postoperative radiochemotherapy was associated with improved OS compared with maintenance TMZ alone, whereas the improvement in PFS did not reach statistical significance. The co-occurrence of chromosome 7 gain and chromosome 10 loss was identified as a significant risk factor for shorter PFS and OS. Exploratory subgroup analyses suggested greater potential benefit in patients with MGMT-unmethylated tumors, IDH wild-type tumors, multiple surgical sites, or Ki-67 < 20%. Given the small sample size, retrospective non-randomized design, and wide confidence intervals in some subgroup estimates, these findings should be interpreted cautiously and validated in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.